- Home
- RARE vs ASGN Comparison
RARE vs ASGN Comparison
Compare RARE & ASGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ASGN
- Stock Information
- Founded
- RARE 2010
- ASGN 1985
- Country
- RARE United States
- ASGN United States
- Employees
- RARE N/A
- ASGN N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ASGN Professional Services
- Sector
- RARE Health Care
- ASGN Consumer Discretionary
- Exchange
- RARE Nasdaq
- ASGN Nasdaq
- Market Cap
- RARE 5.2B
- ASGN 4.2B
- IPO Year
- RARE 2014
- ASGN 1992
- Fundamental
- Price
- RARE $43.98
- ASGN $84.18
- Analyst Decision
- RARE Strong Buy
- ASGN Buy
- Analyst Count
- RARE 14
- ASGN 5
- Target Price
- RARE $88.43
- ASGN $103.40
- AVG Volume (30 Days)
- RARE 717.6K
- ASGN 386.1K
- Earning Date
- RARE 02-13-2025
- ASGN 02-05-2025
- Dividend Yield
- RARE N/A
- ASGN N/A
- EPS Growth
- RARE N/A
- ASGN N/A
- EPS
- RARE N/A
- ASGN 3.96
- Revenue
- RARE $522,745,000.00
- ASGN $4,188,800,000.00
- Revenue This Year
- RARE $27.36
- ASGN N/A
- Revenue Next Year
- RARE $18.61
- ASGN $1.86
- P/E Ratio
- RARE N/A
- ASGN $21.18
- Revenue Growth
- RARE 27.44
- ASGN N/A
- 52 Week Low
- RARE $37.02
- ASGN $82.75
- 52 Week High
- RARE $60.37
- ASGN $106.42
- Technical
- Relative Strength Index (RSI)
- RARE 33.50
- ASGN 38.66
- Support Level
- RARE $41.45
- ASGN $82.75
- Resistance Level
- RARE $50.00
- ASGN $90.45
- Average True Range (ATR)
- RARE 1.83
- ASGN 2.26
- MACD
- RARE -0.31
- ASGN -0.40
- Stochastic Oscillator
- RARE 26.55
- ASGN 24.57
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.